ResHealth 2017
clinical trials:
nova tech flu study

A Phase III Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza

novatech flu trials, respiratory medicine
  • between 18 - 65 years
  • an acute illness compatible with influenza infection (each of the following is required):
  • Oral temperature of ≥ 380C (obtained in office or self-measured within 12 hours prior to screening - if self-measured, subject must also have taken an antipyretic within 4 hours prior to screening) AND
  • At least one of the following respiratory symptoms (cough, sore throat, nasal obstruction) that is considered by the patient to be moderate or severe (greater than mild severity). AND
  • One of the following constitutional symptoms (fatigue, headache, myalgia, feverishness) that is considered by the patient to be moderate or severe (greater than mild severity).
  • Severe illness that will require hospitalisation.
  • Presence of any other pre-existing chronic infection that is undergoing or requiring medical therapy.
  • Flu Vaccination on or after 1/2/2013 - (getting clarified)
affiliated with
follow us
©Copyright 2017. Arasmi.org
Email: info@arasmi.org

Powered by Digital Wave Media